In a world that has gone ever more digital and more data driven, this panel is comprised of industry experts who seek to understand the wealth of opportunities and challenges brought on by big data. The discussion will also be focused on how the different players in the healthcare industry seek to capitalize on this information to help drive more innovation and to improve healthcare outcomes.
Mr. Ash Malik is currently the lead director of the personalized medicine practice at PwC Health Industries Advisory. His primary focus is in helping clients develop transformational business models at the convergence of biopharmaceuticals, diagnostics, and healthcare providers/payers, addressing the impact of genomic data and other patient information in the context of new data analytics and access settings. Ash has over 17 years of molecular diagnostics and pharmaceuticals industry experience, outlining and delivering on product development and commercialization strategies to mitigate business risks, generate profitable growth, and support higher firm valuations.
Prior to joining PwC, Ash led strategic planning at Merck & Co., specifically for companion diagnostic-enabled drugs and biomarkers-to-assay development approaches. Ash also led a product development group at bioMérieux focused on DNA and RNA analyte-based assays. Ash holds a MBA from the Kenan-Flagler Business School at the University of North Carolina and a MS in biochemical engineering from Duke University.
Shahid Azim is the founder and CEO of Quanttus, a wearables startup located in Cambridge leveraging big data based on technology developed at MIT. Prior to this in 2009, he co-founded a company based on research from Mechanical Engineering Department at MIT to launch Lantos Technologies, a novel 3D imaging company. Lantos brought the world's first 3D digital direct scanning of human ear canals to revolutionize the way people experience custom hearing aids and earphones. He was previously the founder and CEO of Braintree Group, a global business process outsourcing firm with 24/7 operations on three continents and was acquired in 2007.
Shahid holds Bachelors in Finance from Seattle University, post graduate in management from Harvard University and an MBA from Sloan School of Management at MIT. He was a Sloan Fellow class of 2009.
Steve received a BS degree in Biology from University of South Florida, Tampa, FL, followed by a Ph.D. in Molecular Pharmacology and Structural Biology from Thomas Jefferson University, Philadelphia, PA. His research work focused on engineering transposons as potential gene therapy delivery agents. Steve's postdoctoral work, performed at Georgia State University, Atlanta, GA, focused on the determination of the solution structure, by high resolution NMR, of retroviral DNA tandem repeats with particular focus on the dynamics of the CA steps.
Following his postdoctoral work, Steve moved to GlaxoSmithKline and focused on data mining activities around predicting hepatocellular toxicity in rat liver models using both transcriptomics and metabonomics data. At Novartis, Steve spent seven years in the Developmental and Molecular Pathways organization focused on applying pathway principles to data mining efforts covering a broad science and technology base. Recently, Steve moved into the IT organization where he leads a global Data Sciences team whose mission is to develop software and big data systems that enable innovative science and scientists at NIBR.
Tom Delbanco, MD, is the Koplow-Tullis Professor of Medicine at Harvard Medical School. Until 2002, he was Chief of the Division of General Medicine and Primary Care at Beth Israel Deaconess Medical Center in Boston, a unit he created and led for more than 30 years. Educated at Harvard College and the Columbia College of Physicians and Surgeons, Dr. Delbanco led the establishment of one of the first primary care practice and teaching programs at an academic health center. Subsequently, he created the Harvard Medical School Faculty Development and Fellowship Program that has now trained more than 250 general internists for academic careers. Dr. Delbanco served in Congress as a Robert Wood Johnson Health Policy Fellow in 1978-9 and is one of the founders of the Society of General Internal Medicine, serving also as its President in 1986. He was the founding Chair of the Picker Institutes in the USA and Europe, organizations that document patient experiences and work with patients to improve health services.
Currently, Dr. Delbanco and his colleague, Jan Walker, are leading "OpenNotes," a national effort to promote and examine the impact of increasing transparency in care by inviting patients to read and contribute to their medical records.
Dr. Rothenhaus joined athenahealth in 2011. As Vice President and Chief Medical Officer, he oversees athenahealth's Network Knowledge division, which focuses on leveraging athenahealth's unique data assets in support of corporate, product and client performance management. In addition, Dr. Rothenhaus leads client solutions for athenaCoordinator, athenahealth's care coordination and population health management service. He also oversees athenahealth's patient safety and research programs.
Dr. Rothenhaus is a nationally recognized expert on the implementation of electronic health record systems and the use of information technology in support of emerging delivery models and the provision of safe, effective, patient-centered care. Prior to joining athenahealth, he was Chief Information Officer of Steward Health Care (formerly the Caritas Christi) the largest community-based health system in New England, where he developed and executed a multi-year, $75 million, capital plan to modernize IT infrastructure and automate care delivery in six hospitals and over one hundred ambulatory medical practices serving 55 communities in eastern Massachusetts.
Dr. Rothenhaus graduated with distinction from the George Washington University School of Medicine, and completed his internship and residency at the George Washington University Hospital. He has a Bachelor's Degree in Biomedical Engineering from Tulane University.
Dr. Salisbury's career has been spent in the personalized medicine and genomics industries. Prior to joining Knome, he served in various scientific and management roles at Genaissance Pharmaceuticals, Clinical Data, and Transgenomic. His expertise spans several areas of genetic research and its clinical application, including molecular diagnostics, personalized medicine, population and statistical genetics, and software and algorithm development. Dr. Salisbury holds degrees in biology from Yale University and the University of Michigan.
